Results 271 to 280 of about 104,861 (298)

Parp inhibitors

2016
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifi cally and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the fi rst to therapeutically exploit mutant recessive cancer genes.
Grève, J.De, Decoster, L., Shahi, R.B., Fontaine, C., Vanacker, L., Pauwels, I., Denayer, E., Brakeleer, S.De, Teugels, E.   +8 more
openaire   +1 more source

A snapshot of chemoresistance to PARP inhibitors

Trends in Pharmacological Sciences, 2012
The exploitation of synthetic lethality in BRCA-deficient tumor carriers using potent inhibitors of the enzyme poly(ADP-ribose) polymerase (PARP)-1 has led to an enthusiastic response among basic scientists, oncologists and pharmaceutical companies. However, accumulating evidence demonstrates that resistance to these drugs develops in tumors in both ...
openaire   +3 more sources

PARP inhibitors in ovarian cancer

Seminars in Oncology
Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency.
Ian S. Goldlust, Elena Guidice, Jung-min Lee   +2 more
openaire   +2 more sources

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

Nature Reviews Clinical Oncology, 2021
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan   +2 more
exaly  

PARP inhibitors plough on

Nature Reviews Drug Discovery, 2017
openaire   +2 more sources

PARP Inhibitors

2014
Joaquin Mateo, Timothy A. Yap, Johann S. De Bono   +2 more
openaire   +1 more source

Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors

Cancer Cell, 2020
Meng Yu, Chen Li, Rong Zeng
exaly  

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

Cancers, 2020
Seock-Ah Im
exaly  

PARP inhibitors: pitfalls and promises

The Lancet Oncology, 2013
Jeffrey R, Infante, Howard A, Burris
openaire   +2 more sources

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Ca-A Cancer Journal for Clinicians, 2011
Timothy A Yap, Shahneen Sandhu, Johann S De Bono   +2 more
exaly